NEW YORK, NY / ACCESSWIRE / December 13, 2018 / U.S. equities closed higher on Wednesday amidst renewed hopes over the U.S.-China trade talks. According to a report in Wall Street Journal, China is working on a plan to expand their access to foreign companies that will support the U.S.-China trade relations, and will replace the Made in China 2025 plan. The Dow Jones Industrial Average gained 0.64 percent to close at 24,527.27, while the S&P 500 Index increased 0.54 percent to close at 2,651.07. The Nasdaq Composite Index climbed 0.95 percent to close at 7,098.31.
The Market Edge Initiates Coverage on:
Alnylam Pharmaceuticals, Inc.
Array BioPharma Inc.
Alnylam Pharmaceuticals' stock jumped 3.53% Wednesday, to close the day at $79.50. The stock recorded a trading volume of 499,309 shares, which was below its three months average volume of 890,342 shares. In the last year, Alnylam Pharmaceuticals' shares have traded in a range of 63.57 - 153.99. The share price has gained 25.06% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $76.71 is below its 200-day moving average of $92.74. Shares of Alnylam Pharmaceuticals have gained roughly 17.05 percent in the past month and are down 37.43 percent year-to-date.
Access The Market Edge's Alnylam Pharmaceuticals, Inc. ResearchReport:
On Wednesday, shares of Array BioPharma recorded a trading volume of 2,135,334 shares, which was below the three months average volume of 2,532,615 shares. The stock ended the day 4.47% higher at $16.14. The share price has fallen 20.14% from its 52 week high with a 52 week trading range of 10.54 - 20.21. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $15.70 is below its 200-day moving average of $15.75. Shares of Array BioPharma have gained roughly 6.89 percent in the past month and are up 26.09 percent year-to-date.
Access The Market Edge's Array BioPharma Inc. Research Report:
The Market Edge
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
The Market Edge has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of MarketEdgeReport.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. MarketEdgeReport.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.marketedgereport.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
The Market Edge, Unit #901 511 Avenue of the Americas, New York, NY, 10011
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: The Market Edge